GlobeNewswire

2024-12-12 05:35

Io Therapeutics, Inc., announces presentation of data from studies of its RAR gamma agonist compound IRX5010 in treatment of a mouse model of triple negative breast cancer, demonstrating combination treatment effects with an anti-PDL-1 monoclonal antibody

SPRING, Texas, Dec. 11, 2024 (GLOBE NEWSWIRE) -- Io Therapeutics, Inc., presented results from studies done in a mouse model of triple negative breast cancer with the company’s newest anti-cancer compound IRX5010, an agonist of the retinoic acid nuclear receptor gamma which was discovered in the company’s oncology drug program. The presentation titled “The RAR gamma nuclear receptor agonist IRX5010 has combination inhibitory effects with an anti-PDL-1 checkpoint inhibitor on the growth of EMT-6 triple negative breast cancer” was delivered as a late-breaking abstract at the San Antonio Breast Cancer Symposium 2024, currently underway in San Antonio, Texas. The poster presentation was authored by Vidyasagar Vuligonda, Ph.D., Chief Scientific Officer of the company and inventor of the compound; and Martin E. Sanders, M.D., the company’s Chief Executive Officer.

The presented studies showed treatment of the EMT-6 mouse model of triple negative breast cancer with IRX5010 plus a checkpoint inhibitor monoclonal anti-PDL-1 resulted in substantial 84% inhibition of tumor growth. This was a 9% increase of inhibitory effect on tumor growth of the combination over treatment with anti-PDL-1 alone. Treatment with IRX5010 increased numbers of tumor-infiltrating effector memory CD4 and CD8 phenotype T-cells (TIL), and inhibited tumor infiltration by granulocytic myeloid derived suppressor cells (gMDSC). Additive or synergistic effects on each of these outcomes were observed with the combination treatment of IRX5010 with anti-PDL-1.

Dr. Vuligonda stated “These findings are the first demonstration of additive and synergistic effects of combination treatment with an RAR gamma nuclear receptor agonist and an anti-PDL-1 monoclonal antibody checkpoint inhibitor in a triple negative breast cancer mouse model. The data presented today add to our growing evidence that IRX5010 has immune-mediated mechanisms of action, including promotion of TIL and inhibition of MDSC, and that these effects are increased in combination with an anti-PDL-1 checkpoint inhibitor. We have previously reported that oral treatment with IRX5010 alone resulted in suppression of growth in mouse models of breast, lung, colon, and prostate cancers. In all four types of these highly prevalent cancers, we observed that IRX5010 induced increased numbers of TIL associated with reduction in tumor growth. With our current studies in triple negative breast cancer, we now add combination effects with anti-PDL-1 of promotion of tumor infiltration by TIL and inhibition of tumor infiltration by MDSC, to the growing list of anti-cancer mechanisms of action of IRX5010.”

Dr. Sanders stated, “IRX5010 has potential to be a new treatment for multiple currently inadequately treated cancers, including triple negative breast cancer, a historically difficult to treat type of cancer. This is supported by its demonstrated mechanisms of action in the immune system of increasing tumor-infiltration of anti-cancer T-cells, while also decreasing tumor infiltration of myeloid derived suppressor cells, a type of cell known to inhibit anti-cancer responses to checkpoint inhibitors. We look forward to translating IRX5010 into clinical trials in patients with triple negative breast cancer.”

About Io Therapeutics: Io Therapeutics, Inc. is a privately held company headquartered in Spring, Texas. More information on Io Therapeutics and its product development programs is available on the company’s web site: www.io-therapeutics.com

Forward Looking Statements: This news release contains “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995.

info@io-therapeutics.com


Primary Logo

source: Io Therapeutics, Inc.

【強免疫‧抗病毒】3大健康法寶低至$88 (徇眾要求 優惠期延長至25年2月21日)► 了解詳情

人氣文章
最近7天
1
專訪 | 關稅戰 | 香港物流協會副會長梁庭彰:美物流商停收包裹對跨境電商打擊重大
2
收市短打 | 楊韻銳:港股升勢有成交配合 惟留意關鍵阻力位!
3
港股 | 午市前瞻 | iPhone SE難救中國市場 專家提醒比電已超買
4
高息定存 | 一周高息合集,蛇年定存金蛇起舞,1個月定存高達8厘
5
港股 | 午市前瞻 | AI應用概念炒作有錢途 下階段部署邊隻好?
6
港股 | 蕭猷華:恒指短線回調,中線繼續看好
7
AI | DeepSeek日活躍用戶達二千萬,據報在港設兩公司
8
神州經脈 | 多國限制用DeepSeek,美郵政恢復收中港包裹
9
iPhone SE 4或於本周內上架官網
10
關稅戰 | 觸發避險金價屢創新高看3000美元,應揀買金礦股抑或黃金ETF?
1
高息定存 | 6個月港元定存3.8厘新高,188日快閃優惠3.68厘
2
港股 | 蕭猷華:內地AI發展迅速,阿里巴巴股價看俏
3
高息定存 | 一周高息合集,銀行高息搶存,富邦1個月4.88厘,華僑1年期3.6厘
4
英偉達 | DeepSeek衝擊AI晶片行業結構 英偉達暴跌仍未急抄底
5
高息定存 | 花旗3個月港元定存息加至4厘,信銀國際3.88厘
6
環球央行 | 歐洲央行宣布再次減息0.25厘,符合市場預期
7
一本萬利 | 2025年的五個「勿」(有片)
8
互聯支付 | 黃俊碩:轉數快與IBPS互聯支付所產生的發展契機
9
啟德體育園明天足球賽測試,4.4萬公僕參與涉逾400萬車馬費
10
高息定存 | 華僑銀行推新春港元定存優惠,88天或188天享3.68厘
11
電騙 | 黃俊碩:多管齊下,防治內地留學生受騙
12
易經看世界 | 乙巳蛇年趨吉五招:言行注意甚麼?應遠離甚麼人?(有片)
13
【FOCUS】去年貿易順差破紀錄,中國擴消費增緊迫感
14
專訪|洪灝:美股更大跌幅在前面,恐需習慣4%通脹(有片)
15
【FOCUS】侵侵就職倒數一周,美元及油價劇本臨揭盅
16
習近平應約與特朗普通電話,特:冀盡快與習見面
17
洪灝專訪 | 淘寶衝擊巨大,港樓價未反映大周期拐點(有片)
18
新世界 | 摩通:新世界若債務違約或打開行業「潘朵拉盒子」
19
雷賢達觀點 | 香港篇:恒指年波幅料六千點,港須全面融入大灣區
20
【FOCUS】螺絲殼裏做道場,DeepSeek致勝啟示
21
專訪 | 關稅戰 | 香港物流協會副會長梁庭彰:美物流商停收包裹對跨境電商打擊重大
22
大S | 台灣藝人徐熙媛因流感併發肺炎逝世,享年48歲
23
高息定存 | 一周高息合集,部分銀行逆市加息,南商3個月加至3.8厘
24
加州山火造成超500億美元損失,大量房主未買保險
25
DeepSeek推出即上蘋果中國區榜首,能力直追OpenAI
26
港股 | 蕭猷華:春節假後,恒指逐步上望21000點
27
收市短打 | 楊韻銳:港股升勢有成交配合 惟留意關鍵阻力位!
28
特朗普就職 | 特朗普上台後行動列表
29
港股 | 午市前瞻 | iPhone SE難救中國市場 專家提醒比電已超買
30
馬斯克明拆特朗普台,指其星際之門計劃「假大空」
專業版
HV2
精裝版
SV2
串流版
IQ 登入
強化版
TQ
強化版
MQ

【etnet 30周年】多重慶祝活動一浪接一浪,好禮連環賞!

【蛇年行大運 新年好賞「飾」】etnet賞太歲開運趨吉避凶神器

etnet榮獲HKEX Awards 2023 「最佳證券數據供應商」大獎

貨幣攻略

大國博弈

說說心理話

聖誕新年特輯

Watch Trends 2024

北上食買玩

Art Month 2024

流感高峰期

山今養生智慧

輕鬆護老